Unlock the most dynamic view of cancer
with our revolutionary precision oncology tests.
Unlock the most dynamic view of cancer with our revolutionary precision oncology tests.
Our liquid and tissue tests answer critical questions across the cancer care continuum—providing end-to-end insights with the convenience of a single testing partner.1-5
Guardant Infinity
technology
turnaround time.§2,3
solid tumors4
—
solid tumors6
Guardant Infinity
technology
solid tumors7
Guardant Infinity
technology
*When compared to other tissue-free testing companies. Comparisons are based on publicly available information as of October 2025.
†Median turnaround time from sample receipt to results.
‡Guardant Reveal is covered by Medicare to guide adjuvant therapy decision-making following surgery and for longitudinal recurrence surveillance every 3 to 6 months in CRC.
§Fastest average turnaround time from sample receipt to results based on stated average turnaround times from Integra Connect data.
¶As a professional service, Guardant360 CDx reports mutations in 74 genes. This report has not been reviewed or approved by the FDA.
#Guardant360® Tissue can be ordered as a standalone or with Guardant360 CDx liquid biopsy. Liquid and tissue testing may be initiated at the same time, but sample processing does not occur concurrently. Once the Guardant360 CDx liquid results have been delivered, confirmation of medical necessity is required to proceed with Guardant360® Tissue. Patients who have a negative Guardant360 CDx test result for an indicated companion diagnostic biomarker should be reflexed to tissue biopsy testing using an FDA-approved tumor tissue test, if feasible.
||Coverage excludes patients with central nervous system tumors.
MRD, minimal or molecular residual disease; MSI, microsatellite instability; TMB, tumor mutation burden.
Important note: Guardant Reveal, Guardant360® Liquid, and Guardant360® Tissue were developed as Laboratory Developed Tests (LDTs), and their performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. These tests have not been cleared or approved by the US FDA.
References: 1. Guardant Reveal Assay Specifications. 2025. Guardant Health, Inc. Redwood City, CA. 2. Guardant Health data on file. September 27, 2024. Guardant Health, Inc. Redwood City, CA. 3. FDA News Release. FDA approves first liquid biopsy next-generation sequencing companion diagnostic test. August 7, 2020. Updated August 11, 2020. Accessed October 8, 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-first-liquid-biopsy-next-generation-sequencing-companion-diagnostic-test 4. Guardant360® CDx Technical Information. Guardant Health, Inc. Redwood City, CA. 5. Guardant360® CDx Assay Specifications. Guardant Health, Inc. Redwood City, CA. 6. Guardant360® Liquid Assay Specifications. October 14, 2024. Guardant Health, Inc. Redwood City, CA. 7. Guardant360® Tissue Assay Specifications. Guardant Health, Inc. Redwood City, CA. 8. Guardant Health data on file. April 1, 2024. Guardant Health, Inc. Redwood City, CA.